Skip to main content
Red Light Holland Corp. logo

Red Light Holland Corp. — Investor Relations & Filings

Ticker · TRIP ISIN · CA75671E1097 LEI · 529900C4CDMRMMH35G80 CSE Agriculture, forestry and fishing
Open in API
Filings indexed 313 across all filing types
Latest filing 2026-04-24 Regulatory Filings
Country CA Canada
Listing CSE TRIP

About Red Light Holland Corp.

https://redlight.co/

Red Light Holland Corp. is engaged in the production, growth, and sale of functional mushrooms, mushroom home grow kits, and psilocybin truffles across North America and Europe. The company supplies premium, recreational-grade magic truffles, primarily under the iMicrodose brand, to the legal adult-use market in the Netherlands. Through its applied science platform, Scarlette Lillie Science and Innovation, the company holds licenses for the research, cultivation, and extraction of various psychedelic and plant-based compounds, including psilocybin, for medicinal and scientific purposes. A key focus is the development of naturally occurring, non-synthetic "whole fungi" psilocybin medicine for future medical markets.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 65% confidence The document is a corporate press release via Newsfile Corp highlighting clinical supply shipments of a drug candidate and general business updates including a pending acquisition mention. It does not present financial results (so it is not an Earnings Release or Interim Report), nor is it a formal Annual Report, audit report, governance proxy, or investor presentation. It is a general business/regulatory announcement that does not fit the other highly specific categories, so it falls under the fallback category of general regulatory filings (RNS).
2026-04-24 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing clinical study results related to a psilocybin therapy drug candidate and highlighting regulatory and policy developments. It does not contain financial statements, detailed financial analysis, or regulatory filings such as 10-K or interim reports. It also does not report on shareholder votes, management changes, or capital structure updates. The content focuses on clinical research outcomes, company strategy, and forward-looking statements, typical of a general corporate announcement or regulatory update. The document length is over 13,000 characters, but it is clearly a news release rather than a formal financial or regulatory filing. Therefore, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other specific categories.
2026-04-20 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing clinical study results related to a psilocybin therapy drug candidate and highlighting regulatory and policy developments. It does not contain financial statements, detailed financial analysis, or regulatory filings. It is not an earnings release, annual report, or interim report. It is not a management or governance report, nor a legal or capital update. The document is informational and promotional in nature, focusing on clinical research outcomes and company strategy. It does not fit into any specific financial or regulatory filing category but is best classified as a general regulatory announcement or miscellaneous filing. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (13,734 characters) is substantial, indicating it is not a brief announcement of a report publication (RPA).
2026-04-20 English
Notice of meeting - English.pdf
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal Notice of Annual General and Special Meeting of Shareholders requesting shareholder votes on corporate matters and referring to the accompanying management information circular and form of proxy. This falls under proxy solicitation materials sent to shareholders to provide meeting information and request votes. Therefore, the appropriate category is Proxy Solicitation & Information Statement (PSI).
2026-04-10 English
Management information circular - English.pdf
Proxy Solicitation & Information Statement Classification · 96% confidence The document is a Notice of Annual General and Special Meeting of Shareholders accompanied by a Management Information Circular (proxy statement) for soliciting proxies at the AGM. It contains detailed proxy solicitation materials (notice, form of proxy instructions, discussion of matters to be voted, record date, voting procedures, the Circular itself). This fits the definition of Proxy Solicitation & Information Statement (PSI).
2026-04-10 English
Form of proxy - English.pdf
Proxy Solicitation & Information Statement Classification · 90% confidence The document is a form of proxy for the Annual General and Special Meeting, soliciting shareholder votes and providing voting instructions and resolutions. This is a typical proxy solicitation document. Therefore, it falls under ‘Proxy Solicitation & Information Statement’ (PSI).
2026-04-10 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.